XNAS 19 May, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| James I. Healy | Director | 04 May 2026 | 2,526,315 | 0 | - | - | Series B Preferred Stock | ||
| James I. Healy | Director | 04 May 2026 | 6,052,631 | 0 | - | - | Series A-2 Preferred Stock | ||
| James I. Healy | Director | 04 May 2026 | 1,927,159 | 1,927,159 | - | - | Common Stock | ||
| James I. Healy | Director | 04 May 2026 | 804,379 | 2,731,538 | - | - | Common Stock | ||
| Antony Loebel | Chief Medical Officer | 30 Apr 2026 | 63,157 | 0 | - | - | Series B Preferred Stock | ||
| Antony Loebel | Chief Medical Officer | 30 Apr 2026 | 20,109 | 20,109 | - | - | Common Stock | ||
| Antony Loebel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 63,680 | 63,680 | - | - | Stock Option (Right to Buy) | |
| Lana Gladstein | General Counsel | 30 Apr 2026 | 105,263 | 0 | - | - | Series B Preferred Stock | ||
| Lana Gladstein | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 63,680 | 63,680 | - | - | Stock Option (Right to Buy) | |
| Lana Gladstein | General Counsel | 30 Apr 2026 | 33,515 | 33,515 | - | - | Common Stock | ||
| Michael Cunyuan Chen | Chief Scientific Officer | 30 Apr 2026 | 10,526 | 0 | - | - | Series B Preferred Stock | ||
| Michael Cunyuan Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 63,680 | 63,680 | - | - | Stock Option (Right to Buy) | |
| Michael Cunyuan Chen | Chief Scientific Officer | 30 Apr 2026 | 3,351 | 3,351 | - | - | Common Stock | ||
| Lauren A. White | Chief Financial Officer | 30 Apr 2026 | 21,052 | 0 | - | - | Series B Preferred Stock | ||
| Lauren A. White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 63,680 | 63,680 | - | - | Stock Option (Right to Buy) | |
| Lauren A. White | Chief Financial Officer | 30 Apr 2026 | 6,702 | 6,702 | - | - | Common Stock | ||
| Daphne Zohar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 1,486,786 | 1,486,786 | - | - | Stock Option (Right to Buy) | |
| Daphne Zohar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 271,813 | 271,813 | - | - | Stock Option (Right to Buy) | |
| Sharon Mates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 49,033 | 49,033 | - | - | Stock Option (Right to Buy) | |
| Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 12,258 | 12,258 | - | - | Stock Option (Right to Buy) | |
| Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 12,258 | 12,258 | - | - | Stock Option (Right to Buy) | |
| Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 991,192 | 991,192 | - | - | Stock Option (Right to Buy) | |
| Steven M. Paul | Director | 30 Apr 2026 | 210,526 | 0 | - | - | Series B Preferred Stock | ||
| Steven M. Paul | Director | 30 Apr 2026 | 67,031 | 863,031 | - | - | Common Stock | ||
| Sandra E. Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 12,258 | 12,258 | - | - | Stock Option (Right to Buy) |